Vivasure Medical

What Vivasure Medical does

Vivasure Medical is a Galway, Ireland-based medical device company founded in 2008 that developed PerQseal, a fully bioabsorbable, sutureless patch-based vascular closure system. The device uses a polydioxanone (PDO) polymer platform applied through a proprietary deployment mechanism to seal large-bore arterial access sites (14–22F, expandable to 26F) created during transcatheter aortic valve replacement (TAVR), endovascular aneurysm repair (EVAR), and other structural heart and endovascular procedures. Its clinical performance — a 97% technical success rate and 0% major device-related complications — positioned it as a differentiated alternative to traditional suture- or plug-based closure methods.

The company's business model centered on direct sales of single-use closure devices to interventional cardiology and vascular surgery hospital departments across Europe and, pending FDA approval, the United States. Pricing follows a premium per-procedure medical device model typical of structural-heart accessories, with revenue tied to procedure volume in target indications. Pre-acquisition, Vivasure generated negligible revenue, having reached CE Mark in April 2025 and treated its first commercial patients in December 2025. The company was funded through multiple venture rounds totaling approximately $99M, supplemented by the European Investment Bank and European Innovation Council.

In January 2026 Vivasure was acquired by Haemonetics for €100M upfront plus up to €85M in milestones, with Haemonetics having previously held a strategic investment stemming from a 2023 financing. The acquisition provides Vivasure with Haemonetics' global vascular closure sales force and hospital relationships, accelerating the commercial rollout that would otherwise have required several years of independent infrastructure build-out.

Name

Vivasure Medical

Legal name

Vivasure Medical Ltd

Website

https://vivasuremedical.com

Company type

Private

Founded year

2009

Operating status

Acquired

Headcount range

11–50 employees

Short description

Vivasure Medical, a Galway-based medical device company, developed PerQseal, a fully bioabsorbable sutureless patch-based large-bore vascular closure device for TAVR, EVAR, and structural heart procedures. Acquired by Haemonetics in January 2026.

Ownership category

akta.pro rank

Product category

Vascular Closure Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Vascular Access & Closure Devices (Sheaths, Guidewires, Closure Systems) (HLAHAFAK)

Keywords

• Vascular closure devices
• Bioabsorbable implants
• Endovascular closure systems
• Medical device manufacturing
• Large-bore vessel closure

Headquarters

HQ city

Galway

HQ country

Ireland

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Medical Device Sales: Vivasure Medical generated revenue through sales of its PerQseal vascular closure devices. Prior to acquisition, the company had accumulated losses exceeding €125 million by end of 2024, indicating limited commercial revenue during development phase.
2. Product Portfolio Expansion (Post-Acquisition): Following acquisition by Haemonetics in January 2026, PerQseal Elite will be integrated into Haemonetics' Interventional Technologies portfolio targeting the large-bore closure market estimated at $300 million.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

Vivasure Medical develops and manufactures the PerQseal Elite system, a 100% bio-absorbable, sutureless patch-based vascular closure device for large-bore arterial and venous access (sheath sizes 14-22F, arteriotomy/venotomy up to 26F) following transcatheter structural heart and endovascular procedures. The implant is made from Polydioxanone (PDO) polymer that fully biodegrades within 180 days, restoring the vessel to its natural state without sutures, collagen, or metal implants.

Product overview

Vivasure Medical offers the PerQseal Elite system — a breakthrough vascular closure technology platform comprising the PerQseal Elite Closure Device and PerQseal Elite Introducer Sheath. The PerQseal Elite is the first and only 100% bio-absorbable, sutureless patch-based large-bore closure system designed specifically for arterial and venous access in structural heart and endovascular procedures. The system eliminates the need for sutures, collagen, or metal implants, utilizing advanced Polydioxanone (PDO) polymer technology that fully biodegrades within 180 days, restoring the vessel to its natural state. CE Mark approved in Europe for both arterial and venous indications, with FDA Premarket Approval application submitted.

Differentiator

Problem solved

Functional benefit

Brands

• PerQseal: PerQseal is the flagship technology platform - a 100% bio-absorbable, sutureless patch-based large-bore closure system designed for arterial and venous access in structural heart and endovascular procedures. PerQseal Elite received CE Mark approval in Europe in April 2025.
• PerQseal Elite

Products and services

• PerQseal Elite Closure Device A 100% bio-absorbable, sutureless, patch-based closure device for percutaneous sealing of common femoral arteriotomies and venotomies following interventional therapeutic endovascular procedures. Made from Polydioxanone (PDO) that fully biodegrades within 180 days, restoring the vessel to its natural state. Achieved 97% technical success rate with 0% major device-related complications in clinical studies (Elite Arterial Study P935-00). CE Mark approved for both arterial and venous indications.
• PerQseal Elite Introducer Sheath An integral component of the PerQseal Elite system that facilitates vascular access during interventional procedures and works in conjunction with the PerQseal Elite Closure Device for vessel sealing. Supports 0.35" guidewire compatibility and maintains safety wire access during the closure procedure.

Quantifiable outcome

• 97% technical success rate in per-protocol population (Elite Arterial Study P935-00)
• +3 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• Haemonetics CorporationcoreStrategic or Co-development Partner · 9 January 2026Haemonetics acquired Vivasure Medical in January 2026 for €100 million upfront cash payment plus up to €85 million in contingent milestone payments. The acquisition expands Haemonetics' closure device portfolio and strengthens its position in the large-bore closure market for structural heart and endovascular procedures. PerQseal Elite technology complements Haemonetics' existing Interventional Technologies portfolio.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Teleflex: Teleflex's Manta large-bore vascular closure device directly competes with PerQseal Elite in the same sheath-size range and structural-heart / endovascular procedure mix.
• W. L. Gore & Associates: Gore manufactures vascular grafts, sutures, and closure-related endovascular products serving the same structural-heart and endovascular repair procedures that generate demand for large-bore closure systems.
• Terumo: Terumo's Angio-Seal is a leading vascular closure device used across interventional cardiology procedures, overlapping with PerQseal Elite's addressable hospital accounts and customer base.
• Abbott: Abbott markets ProGlide and Perclose suture-mediated vascular closure devices, the most widely used large-bore closure systems in TAVR/EVAR procedures globally — the same procedure categories PerQseal Elite targets.

Broad incumbents

• Haemonetics Corporation: Now Vivasure's parent, Haemonetics' broader Interventional Technologies portfolio (including vascular closure and hospital equipment) overlaps with and distributes PerQseal Elite — the same platform Vivasure developed.
• Cardinal Health (Cordis): Cardinal Health's Cordis franchise distributes interventional cardiology devices including vascular access and closure products, supplying the same hospital cardiology departments that procure PerQseal Elite.
• Medtronic: Medtronic has a broad cardiovascular portfolio spanning structural heart and endovascular procedures, and competes for the same hospital cath-lab accounts that buy large-bore closure devices.
• B. Braun: B. Braun manufactures vascular access sheaths and interventional products used in the same catheter-based procedures (TAVR, EVAR) that drive demand for large-bore closure devices like PerQseal Elite.
• Edwards Lifesciences: Edwards is the leading transcatheter aortic valve (TAVR) manufacturer and is the primary procedure-side driver of large-bore closure demand — PerQseal Elite's largest use case is post-TAVR closure.

Emerging players

• InSeal Medical: InSeal Medical is an emerging European medtech developing a bioabsorbable, sutureless large-bore vascular closure device — the closest technology parallel to Vivasure's PerQseal platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/vivasure-medical

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds6 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vivasure Medical